Exposure to Aromatic Amines and ras and c-erbB-2, Overexpression in Bladder Cancer

Journal of Occupational and Environmental Medicine

Volumn 38, Issue 4, 1996, Pages 390-393

  Novara, Rosanna ^a   Coda, Renato ^a   Martone, Tiziana ^a   Vineis, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 NAPHTHYLAMINE; AROMATIC AMINE; BENZIDINE; CARCINOGEN;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CHEMICAL CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OCCUPATIONAL EXPOSURE; ONCOGENE C ERB; ONCOGENE RAS;

2-NAPHTHYLAMINE; ADULT; AGED; BENZIDINES; CARCINOGENS; CHEMICAL INDUSTRY; HUMANS; ITALY; MALE; MIDDLE AGED; OCCUPATIONAL DISEASES; RAS PROTEINS; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS;

EID: 0029923423     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043764-199604000-00017     Document Type: Article

References (26)

1. Shields P, Harris CC. Molecular epidemiology and the genetics of environmental cancer. JAMA. 1991;266:681-687.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science. 1991;252:49-53.
3. Vahakangas KH, Samet JM, Metcalf RA. Mutations of p53 and ras genes in radonassociated lung cancer from uranium miners. Lancet. 1992;339:576-580.
4. Reynolds SH, Patterson RM, Mennear JH, Maronpot RR, Anderson MW. ras gene activation in rat tumours induced by benzidine congeners and derived dyes. Cancer Res. 1990;50:266-272.
5. Fujita J, Ohuchi N, Ito N, et al. Activation of H-ras oncogene in rat bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. J Natl Cancer Inst. 1988;80:37-43.
6. Czerniak B, Cohen GL, Etkind P, et al. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol. 1992;23:1199-1204.
7. Czerniak B, Deitch D, Simmons H, Herz F, Koss LG. Ha-ras gene codon 12 mutation and DNA ploidy in urinary bladder carcinoma. Br J Cancer. 1990;62:762-763.
8. Burchill SA, Lunec J, Mellon K, Neal DE. Analysis of Ha-ras mutations in primary human bladder tumours. Br J Cancer. 1991;63 (suppl 13):62.
9. Ting-jie M, Ze W, Nianli S. Correlation between the expression of the p21 ras oncogene product and the biological behaviour of bladder tumours. Eur Urol. 1991;20:307-310.
10. Theodorescu D, Cornil I, Fernandez BJ, Kerbel R. Overexpression of normal and mutated forms of H-ras induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci USA. 1990;87:9047-9051.
11. Meyers FG, Gumerlock PH, Kokokis SP, De Verewhite MW, McCormick F. Human bladder and colon carcinomas contain activated ras p21. Cancer. 1989;63: 2177-2181.
12. Fujita J, Yoshida O, Yuasa Y, Rhim JS, Hatanaka M, Aaronson M. Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours. Nature. 1984;309:464-466.
13. Ding-wei Y, Jia-Fu Z, Song-Xi Q, Yong-Jang MA. Correlation between the expression of oncogenes ras and c-erbB-2 and biological behaviour of bladder tumours. Urol Res. 1993;21:39-43.
14. Lipponen P. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer. 1993;29A:749-753.
15. Coombs LM, Pigott DA, Sweeney E, et al. Amplification and overexpression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer. 1991; 63:601-608.
16. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Home CHW. Expression of mutant p53, c-erbB-2 and epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer. 1991;63:967-970.
17. Lipponen P, Eskelinen M, Syrianen S, Tervahauta A, Syrianen K. Use of immunohistochemically demonstrated c-erbB-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol. 1991;20:238-242.
18. Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, Okuhara E, Akiyama T, Toyoshima K, Yamamoto T, Kato T. An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer. 1991;70:2493-2498.
19. Moriyama M, Akiyama T, Yamamoto T, et al. Expression of c-erbB-2 gene product in urinary bladder cancer. J Urol. 1991;145:423-427.
20. Wright C, Mellon K, Neal DE, Johnston P, Corbem JP, Horne CHW. Expression of c-erbB-2 protein product in bladder cancer. Br J Cancer. 1990;62:764-765.
21. Piolatto G, Negri E, La Vecchia C, Pira E, Decarli A, Peto J. Bladder cancer mortality of workers exposed to aromatic amines: an updated analysis. Br J Cancer. 1991;63:457-459.
22. Vineis P, Magnani C. Occupation and bladder cancer in males: a case-control study. Int J Cancer. 1985;35:599-606.
23. Tomatis L (ed.) Cancer: causes, occurrence, control. IARC Sci. Publ. 1990;100: 1-352.
24. Knuechel R, Burgau M, Rueshoff J, Hofstaedter F. Proliferating cell nuclear antigen in normal urothelium and urothelial lesions of the urinary bladder: a quantitative assessment using a true color image analysis system. Virchows Archiv B Cell Pathol. 1993;64:137-144.
25. Hayes RB, Friedell GH, Zahm SH, Cole P. Are the known bladder cancer risk-factors associated with more advanced bladder cancer? Cancer Causes Control. 1993;4:157-162.
26. Brooks DR, Geller AC, Chang J, Miller DR. Occupation, smoking, and the risk of high-grade invasive bladder cancer in Missouri. Am J Ind Med. 1992;21:699-713.